Post by INiTS | Vienna's High-Tech Incubator

What really makes a Life Science or MedTech startup investable? From Pre-Seed to Series B/C, investor expectations shift dramatically. Understanding that evolution can make or break your fundraising strategy. Join us on 25 June 2026 at 17:00 at INiTS in Vienna for an exclusive panel discussion with leading investors across the full financing spectrum. Expect candid insights into how investment decisions are actually made — from early-stage bets to growth-stage scaling. On stage: Guido Boehmelt, Curie.Bio Ingrid Kelly Spillmann, xista science ventures Werner Lanthaler, Wlanholding Paul Sunzenauer, OCCIDENT Moderated by Markus Pietzka, INiTS We will dive into: → How investors determine when a Life Science or MedTech idea becomes investable including early red flags “minimum traction” and how diligence evolves from Seed to Series A and beyond → How different investor types think (angels vs seed VCs) and where value is created across the investment lifecycle → What Series B/C investors prioritize including the balance between growth profitability and exit strategy → How venture capital works at fund level including portfolio construction and why a small number of breakout companies drive most returns → How macroeconomic and geopolitical conditions influence investment appetite and portfolio management in practice If you are building, #investing in, or simply curious about how #LifeScience and #MedTech ventures are funded, this is a conversation worth joining. Secure your spot now >>> https://lnkd.in/dk6GwQmT